The influence of selective serotonin reuptake inhibitors on human platelet serotonin.
Clinical depression has been proposed to be an independent risk factor for cardiovascular disease. While it is suggested that selective serotonin reuptake inhibitors (SSRIs) reduce the risk of acute cardiovascular problems of depressed patients, the effect of SSRIs on platelets, the only blood cells committed to serotonin (5-HT) transport, remains largely unknown. The goal of this pilot study was to measure the 5-HT levels in platelets of untreated and SSRI-treated depressed patients and normal subjects and to determine whether the interaction of SSRIs with platelets can explain their possible cardiovascular benefit in patients with depression. Platelet 5-HT was determined by an immunocytochemical assay and high-pressure liquid chromatography with electrochemical detection (HPLC-ECD). In normal control subjects without cardiovascular disease, 78 +/- 8% of platelets were 5-HT-positive (n = 14). Depression caused a significant reduction in platelet 5-HT to 46 +/- 21% in untreated patients (n = 13) and 22 +/- 13% in SSRI-treated patients (n = 14). As a class, all selective serotonin reuptake inhibitors significantly reduced the 5-HT concentration in patient platelets. An inverse relationship of 5-HT level and dose of medication might be suggested. These results correlated well with 5-HT data from HPLC (r = 0.8509, p < 0.001). SSRIs did not affect platelet aggregation and dense granule release in response to thrombin, but significantly reduced ADP-induced platelet aggregation and dense granule release in both patient and normal control samples. The active inhibition of platelet aggregation by SSRIs might explain their cardiovascular benefit.
Maurer-Spurej
Elisabeth
E
Canadian Blood Services/University of British Columbia Pathology & Laboratory Medicine 2211 Wesbrook Mall Vancouver, BC, V6T 2B5, Canada. emaurer@interchange.ubc.ca
Pittendreigh
Cheryl
C
Solomons
Kevin
K
D000244:Adenosine Diphosphate / Q000378:metabolism; D000255:Adenosine Triphosphate / Q000737:chemistry; D000328:Adult; D001692:Biological Transport; D001792:Blood Platelets / Q000187:drug effects; D016022:Case-Control Studies; D002851:Chromatography, High Pressure Liquid; D003863:Depression / Q000188:drug therapy*; D004563:Electrochemistry; D005260:Female; D005434:Flow Cytometry; D006801:Humans; D007150:Immunohistochemistry; D008297:Male; D008856:Microscopy, Fluorescence; D008858:Microscopy, Phase-Contrast; D008875:Middle Aged; D008954:Models, Biological; D012701:Serotonin / Q000737:chemistry* / Q000378:metabolism; D017367:Selective Serotonin Reuptake Inhibitors / Q000494:pharmacology*; D013917:Thrombin / Q000378:metabolism
D000244:Adenosine Diphosphate; D000255:Adenosine Triphosphate; D012701:Serotonin; D017367:Selective Serotonin Reuptake Inhibitors; D013917:Thrombin